Evidence map›Paper›PMID 30106347›Full record

ArticleRadiology2018

Mapping Drug Dose Distribution on CT Images Following Transarterial Chemoembolization with Radiopaque Drug-Eluting Beads in a Rabbit Tumor Model.

Andrew S Mikhail, William F Pritchard, Ayele H Negussie, Venkatesh P Krishnasamy, Daniel B Amchin, John G Thompson, Paul G Wakim, David Woods, Ivane Bakhutashvili, Juan A Esparza-Trujillo and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 4 countries.

Andrew S MikhailFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).ORCID 0000-0001-9206-5765
William F PritchardFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
Ayele H NegussieFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
Venkatesh P KrishnasamyFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
Daniel B AmchinFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
John G ThompsonFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
Paul G WakimFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
David WoodsFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
Ivane BakhutashviliFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
Juan A Esparza-TrujilloFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
John W KaranianFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
Sean L WillisFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
Andrew L LewisFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
Elliot B LevyFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).
Bradford J WoodFrom the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for Cancer Research (B.J.W.), and Biostatistics and Clinical Epidemiology Service, Clinical Center (P.G.W.), National Institutes of Health, 10 Center Dr, Bethesda, MD 20892, and Biocompatibles UK, BTG International Group, Camberley, England (S.L.W., A.L.L.).ORCID 0000-0002-4297-0051
National Cancer Institute · MYNational Institutes of Health · USCancer Institute (WIA) · IN

Funding

Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
Interventional OncologyZIACL040015 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
$0k
Intramural NIH HHS ZIA CL040015Intramural NIH HHS ZID BC011242
6 · The paper itself

Abstract

Purpose To correlate bead location and attenuation on CT images with the quantity and distribution of drug delivered to the liver following transarterial chemoembolization (TACE) with radiopaque drug-eluting beads (DEB) in a rabbit tumor model. Materials and Methods All procedures were performed with a protocol approved by the Institutional Animal Care and Use Committee. TACE was performed in rabbits (n = 4) bearing VX2 liver tumors by using radiopaque DEB (70-150 µm) loaded with doxorubicin (DOX). Livers were resected 1 hour after embolization, immediately frozen, and cut by using liver-specific three-dimensional-printed molds for colocalization of liver specimens and CT imaging. DOX penetration into tissue surrounding beads was evaluated with fluorescence microscopy. DOX levels in liver specimens were predicted by using statistical models correlating DOX content measured in tissue with bead volume and attenuation measured on CT images. Model predictions were then compared with actual measured DOX concentrations to assess the models' predictive power. Results Eluted DOX remained in close proximity (<600 µm) to beads in the liver 1 hour after TACE. Bead volume and attenuation measured on CT images demonstrated positive linear correlations (0.950 and 0.965, respectively) with DOX content in liver specimens. DOX content model predictions based on CT images were accurate compared with actual liver DOX levels at 1 hour. Conclusion CT may be used to estimate drug dose delivery and distribution in the liver following transarterial chemoembolization (TACE) with doxorubicin-loaded radiopaque drug-eluting beads (DEB). Although speculative, this informational map might be helpful in planning and understanding the spatial effects of TACE with DEB. © RSNA, 2018.

Indexed as

AnimalsAntibiotics, AntineoplasticChemoembolization, TherapeuticDisease Models, AnimalDoxorubicinDrug Delivery SystemsLiverLiver NeoplasmsMicrospheresRabbitsTomography, X-Ray ComputedAntibiotics, AntineoplasticDoxorubicin

Identifiers

PMID30106347
PMCPMC6219695
OpenAlexW2887937775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.